Dietary intervention focused on phosphate intake in hemodialysis patients with hyperphosphoremia

Clin Nephrol. 2012 Jun;77(6):476-83.

Abstract

Background: Elevated serum phosphorus has been identified as a cardiovascular risk factor. This study aimed to assess the effectiveness of dietary intervention to reduce phosphorus intake and to improve the calcium-phosphorus metabolism in hemodialysis patients.

Design: Patients were included in a 6-month, 2-group experimental study if their previous 3-month average serum phosphorus was over 5.5 mg/dl. Patients were allocated to intensive dietary intervention or usual dietary recommendations. The clinical end-points were the multivariate-adjusted change in serum phosphorus and the number of patients who achieved serum phosphorus levels of < 5.5 mg/dl and serum phosphorus levels of < 5 mg/dl.

Results: 80 dialysis patients completed the study, 41 in the experimental group and 39 in the control group. After 6 months, phosphorus intake (702 ± 168 vs. 872 ± 242 mg/24 h; p = 0.002) was lower in the experimental group than in the control group, with no inter-group differences in protein-caloric intake. Serum phosphorus decreased 1.67 mg/dl in the experimental group and 0.58 mg/dl in the control group (multivariate-adjusted difference 0.93 mg/ dl; 95% CI 0.34 - 1.52; p = 0.003). Serum phosphorus < 5.5 mg/dl and serum phosphorus < 5 mg/dl were attained more frequently in the experimental group (51 vs. 18%, p = 0.002 and 31.7 vs. 15.4%, p = 0.08 respectively).

Conclusions: Intensive dietary intervention focusing on phosphorus intake may be useful to reduce phosphorus retention and to improve calcium-phosphorus metabolism in hemodialysis patients.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Biomarkers / blood
  • Calcium / blood
  • Chi-Square Distribution
  • Female
  • Humans
  • Hyperphosphatemia / blood
  • Hyperphosphatemia / diet therapy*
  • Hyperphosphatemia / etiology
  • Kidney Diseases / blood
  • Kidney Diseases / therapy*
  • Linear Models
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Odds Ratio
  • Parathyroid Hormone / blood
  • Phosphorus / blood*
  • Phosphorus, Dietary / adverse effects*
  • Renal Dialysis / adverse effects*
  • Spain
  • Time Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • PTH protein, human
  • Parathyroid Hormone
  • Phosphorus, Dietary
  • Phosphorus
  • Calcium